Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer

Active, not recruiting

Conditions: Non-Metastatic Breast Cancer

Interventions: Other: Clinical Assessments
Behavioral: Questionnaires
Other: Saliva sample

First Posted Date: 2015-08-20

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 546

Registration Number: NCT02530177

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Phase 2

Completed

Conditions: Lung Cancer
Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Interventions: Drug: albumin-bound paclitaxel
Drug: gemcitabine

First Posted Date: 2015-08-17

Last Posted Date: 2021-01-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT02525653

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Sleepy Hollow, New York, United States
🇺🇸
Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States
🇺🇸
Miami Cancer Institute Baptist Health South Florida, Miami, Florida, United States

and more 3 locations

Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection

Phase 3

Active, not recruiting

Conditions: Liver Cancer
Pain Management

Interventions: Other: PCEA
Other: IV PCA

First Posted Date: 2015-08-14

Last Posted Date: 2023-09-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 231

Registration Number: NCT02523443

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack (Consent Only), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center (Consent Only), Basking Ridge, New Jersey, United States

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Device: KIBUR MICRODEVICE
Drug: anthracycline and taxane based chemotherapy

First Posted Date: 2015-08-13

Last Posted Date: 2024-08-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT02521363

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 3 locations

Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors

Not Applicable

Terminated

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Induction Chemotherapy
Procedure: G-PBSC Infusion

First Posted Date: 2015-08-11

Last Posted Date: 2018-04-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT02519712

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Randomized Controlled Trial Examining Health Care Access Interventions for Taxi Drivers

Not Applicable

Active, not recruiting

Conditions: Healthcare Access for Taxi Drivers

Interventions: Behavioral: questionnaires

First Posted Date: 2015-07-24

Last Posted Date: 2024-08-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 756

Registration Number: NCT02508363

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology

Recruiting

Conditions: Head and Neck Cancer
Squamous Cell Carcinoma (SCC) of the Oral Cavity

Interventions: Device: Reflectance Confocal Microscopy

First Posted Date: 2015-07-23

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 140

Registration Number: NCT02507141

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (consent only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (consent only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Phase 2

Active, not recruiting

Conditions: Recurrent Osteosarcoma

Interventions: Biological: humanized anti-GD2 antibody
Drug: GM-CSF

First Posted Date: 2015-07-20

Last Posted Date: 2024-10-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 46

Registration Number: NCT02502786

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Children's Hospital of Los Angeles (Data Collection Only), Los Angeles, California, United States
🇺🇸
MD ANDERSON CANCER CENTER (Data Collection Only), Houston, Texas, United States

Caregiver Burden Within the Ambulatory Extended Recovery (AXR) Patient Population

Completed

Conditions: Caregiver Burden

Interventions: Behavioral: Caregiver Reaction Assessment (CRA)
Behavioral: The Caregiver Quality of Life - Cancer (CQOLC)

First Posted Date: 2015-07-17

Last Posted Date: 2018-08-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 47

Registration Number: NCT02501785

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumors

Interventions: Procedure: Production of Genetically-modified T cells
Drug: Cyclophosphamide
Device: IP Catheter Insertion
Genetic: Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells
Drug: Fludarabine

First Posted Date: 2015-07-15

Last Posted Date: 2024-07-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT02498912

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy